Insulins today and beyond (Q34365284)

1 August 2017

1 reference

title

Insulins today and beyond (English)

1 reference

1 August 2017

D R Owens

1

1 reference

1 August 2017

B Zinman

series ordinal

2

1 reference

1 August 2017

G B Bolli

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

358

1 reference

1 August 2017

issue

9283

1 reference

1 August 2017

page(s)

739-746

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

1 reference

7 January 2021

Insulin analogues and their potential in the management of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Insulin analogs with improved pharmacokinetic profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

The physiologic replacement of insulin. An elusive goal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

1 reference

7 January 2021

Insulin aspart: a novel rapid-acting human insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Hypoglycemia and insulin analogues: is there a reduction in the incidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Insulin lispro in CSII: results of a double-blind crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Metabolic and immunologic effects of insulin lispro in gestational diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Optimal administration of lispro insulin in hyperglycemic type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Variation in125i-insulin absorption and blood glucose concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Study of porcine and human isophane (NPH) insulins in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Demonstration of a relatively hepatoselective effect of covalent insulin dimers on glucose metabolism in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl-insulin complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Reduced Solubility of Short-Acting Soluble Insulins when Mixed with Longer-Acting Insulins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

The effect of mixing human soluble and human crystalline zinc-suspension insulin: plasma insulin and blood glucose profiles after subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905842-1

7 January 2021

10.1016/S0140-6736(01)05842-1

Identifiers

DOI

1 reference

1 August 2017

1 reference